PROPHASE LABS INC. - COMMON STOCK
5.4500
03-May-24 11:41:06
15 minutes delayed
Stocks
+0.1400
+2.64%
Today's range
5.2000 - 5.4900
ISIN
N/A
Source
NASDAQ
-
28 Apr 2023 08:30:00 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Launch of Redesigned Corporate Website
25 Apr 2023 08:30:00 By Nasdaq GlobeNewswire
-
18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Record Financial Results for the year ended December 31, 2022
28 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
21 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces New $6 Million Stock Repurchase Program
15 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test
13 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
07 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
01 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)
22 Feb 2023 08:00:02 By Nasdaq GlobeNewswire
-
16 Feb 2023 08:00:00 By Nasdaq GlobeNewswire
-
15 Feb 2023 08:00:00 By Nasdaq GlobeNewswire
-
06 Feb 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
05 Jan 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
19 Dec 2022 08:30:00 By Nasdaq GlobeNewswire
-
30 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
10 Nov 2022 08:00:04 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute
08 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs to Present at Investor Summit Group’s Q4 Conference
07 Nov 2022 19:12:00 By Nasdaq GlobeNewswire
-
04 Nov 2022 08:00:00 By Nasdaq GlobeNewswire